Clinical Research Directory

Key Inclusion Criteria: * Must be healthy adult and have a body mass index (BMI) 18 through 30 kilograms per square meter (kg/m\^2). * Males must practice highly effective contraception and females must be of no childbearing potential. Key Exclusion Criteria: * Conditions that influence cerebrospinal fluid (CSF) kinetics e.g., significant scoliosis or a physical disability that limits mobility. * Contraindication to: * Magnetic resonance imaging (MRI) scan: e.g., indwelling ferrous metal, implanted medical devices, or claustrophobia. * Radiation/PET scan: e.g., inability to lie flat or still for the duration of the scan) or intolerance to previous nuclear medicine scans. * Lumbar Puncture (LP, spinal tap): e.g., current use of a medication that prolongs coagulation times, including aspirin, known disorders of the coagulation cascade, platelet function, or platelet count, low white blood cell counts, chronic low back pain; prior lumbar spine surgery, anatomical factors at or near the spinal tap site, clinical signs of raised intracranial pressure (e.g., headache, or focal neurologic signs). * Findings from the screening MRI that may interfere with participant safety or the scientific integrity of the study e.g., Chiari malformation, high grade spinal stenosis, hydrocephalus, or neural tube defect. * Abnormal Laboratory Values e.g., liver functions, anemia, abnormal blood coagulation profile. * Cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or malignant disease. * Severe allergic or anaphylactic reactions/ systemic hypersensitivity to diranersen or any component of the study treatment. * Alcohol or substance abuse. * Plans to undergo elective procedures or surgeries during the study. * Enrollment in any other drug, biologic, device, or clinical study within 30 days or 5 half-lives, whichever is longer, prior to Check-in. * Use of any prescription medication (except hormone therapy), over-the-counter medication (excluding acetaminophen), or dietary and herbal supplements (e.g., St. John's wort) within 28 days of the of dosing and during the study. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.